• PL 20 (Tukholmankatu 8)

    00014

    Suomi

1999 …2025

Tutkimustuotoksia vuodessa

Henkilökohtainen profiili

Tutkimuksen ja opetuksen kuvaus

Vilja Pietiäinen’s (Adj. Prof., PhD) research is focused on cancer precision medicine and functional drug testing of solid tumors. The patient -derived cancer cells are isolated from tissues after the surgery, grown ex-vivo, and characterized with different omics technologies, including genomics, phenomics, and drug profiling. Dr. Pietiäinen develops also microscopic imaging –based solutions with her collaborators for phenotyping and drug profiling of patient –derived cells. This approach enables the better understanding of the cellular heterogeneity in cancer, and drug sensitivity and resistance in particular patient.

Vilja Pietiäinen has a M.Sc. in clinical biochemistry (Faculty of Biosciences, University of Helsinki; UH, and University of Edinburgh, Scotland, U.K) and doctoral degree in virology (UH, Finland) and she is a docent in the cellular and molecular biology. In the Academy of Finland post-doctoral position (Research group of Prof. Elina Ikonen, UH), she investigated the intracellular cholesterol trafficking and combined her earlier experience in cell biology, real-time cell imaging and other microscopic methods with lipid research. In 2011-2013, her research project was focused on characterization of novel candidate genes affecting blood lipid levels (such as LDL, HDL, and triglycerides) in humans using high throughput siRNA/drug screening and high-content microscopy in FIMM.

Currently, Dr. Pietiäinen is a senior researcher at Kallioniemi group, and she acts a team leader in iCAN-Flagship iCAN-PEDI/PREPAIR and DEDUCER projects. She is also a partner in iCAN-COMPORG subproject and participates actively in iCAN Data Platform Development (iMTB). Earlier, she led a collaborative project with UPM on novel high-content 3D cell culture methods, and worked as a project manager of TEKES FiDiPro fellow project “Next generation image analysis solutions - towards image-based diagnostics”.  In 2017, she initiated of the new HiLIFE core unit, FIMM High Content Imaging and Analysis (FIMM-HCA) within the HELMI platform, and acts currently as a core director.

She has teaching experience as a teacher at University of Helsinki laboratory courses, a tutor at Problem Based Learning sessions for Medical Students, and as a lecturer. More recently, she has also participated in planning of different courses in the curriculum of Medical Faculty (e.g. Big Data and AI for clinical medicine) and curriculum/new MSc track planning for Master Program for Genetics and Molecular Biosciences. She has studied the pedagogics in several courses at University of Helsinki. Currently, she acts as a part-time coordinator of undergraduate education at FIMM.

Koulutus / tieteellinen pätevyys

Solu- ja molekyylibiologia, dosentti, Helsingin Yliopisto, Bio- ja Ympäristötieteellinen Tiedekunta

Myöntöpäivä: 19 marrask. 2019

Virologia ja Solubiologia, FT, Pikornavirusinfektion soluvuorovaikutukset, Helsingin yliopisto, virologian osasto

Tieteenalat

  • 3111 Biolääketieteet
  • Cancer biology
  • Cancer cell biology
  • Precision medicine
  • 318 Lääketieteen bioteknologia
  • High throughput screening
  • Imaging
  • Microscopy
  • Functional drug testing
  • Drug testing
  • 1182 Biokemia, solu- ja molekyylibiologia
  • Cell Biology
  • 1184 Genetiikka, kehitysbiologia, fysiologia
  • 3122 Syöpätaudit

Kansainvälinen ja kotimainen yhteistyö

Viimeisin maa-/aluetasolla toteutettu yhteistyö. Saat tarkempia lisätietoja pisteitä napauttamalla, tai